Physicians' Academy for Cardiovascular Education

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESc 2016 in Rome

Video navigation menu

  • Incidence of diabetes 00:06
  • Multifactorial prevention of CV morbidity and mortality 02:51
  • Glucose-lowering medication – GLP-1 inhibitor liraglutide in the LEADER trial 07:56
  • Glucose-lowering medication – SGLT2 inhibitor empagliflozin in the EMPA-REG OUTCOME trial 08:41

Educational information

Educational objectives of this symposium were to:

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


Professor John Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom


Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also watch lecture: Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift? by prof John McMurray, MD University of Glasgow United Kingdom Also watch lecture: Overview of SGLT-2 inhibitors in T2DM management: current position & future promise by prof Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA

Share this page with your colleagues and friends: